NCT05036681 2026-03-27
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
24 trialsNCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT05603910 2026-02-24
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
University of Miami
Phase 1 Recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05761951 2026-02-11
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03932409 2026-02-10
FIERCE
University of Oklahoma
Phase 1 Active not recruiting
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT02899793 2025-06-11
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Yale University
Phase 2 Completed
NCT03835819 2025-05-15
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06502743 2025-04-03
PENELOPE
Yonsei University
Phase 2 Recruiting
NCT02630823 2025-01-03
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
Phase 1 Completed
NCT06549855 2024-08-12
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Peking University People's Hospital
Phase NA Not yet recruiting
NCT02728830 2024-02-21
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Duke University
Phase EARLY_PHASE1 Completed
NCT06180733 2023-12-22
PAM-II
University Medical Center Groningen
Phase 2 Recruiting
NCT03694834 2023-11-28
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT05419817 2023-02-27
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
University of Pittsburgh
Phase 2 Withdrawn
NCT04014530 2023-02-01
ATAPEMBRO
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Recruiting
NCT02549209 2022-03-02
Pembro/Carbo/Taxol in Endometrial Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT04611139 2022-03-02
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
HonorHealth Research Institute
Phase 1 Withdrawn
NCT03276013 2021-10-05
TOPIC
Vall d'Hebron Institute of Oncology
Phase 2 Completed
NCT03192059 2021-09-08
PRIMMO
University Hospital, Ghent
Phase 2 Completed
NCT04197219 2020-11-05
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn